FDA grants priority review for a new four-weekly, fixed-dose regimen of durvalumab for treatment of non-small cell lung cancer (NSCLC) and bladder cancer

If approved, the drug could be administered IV every 4 weeks at fixed dose of 1500mg in unresectable stage III NSCLC after chemoradiation therapy and previously treated advanced bladder cancer, as alternative to approved weight-based dosing of 10mg/kg every 2 weeks.